The vaccine uses plasmid DNA encoding human epidermal growth factor receptor 2 (HER-2) and carcinoembryonic antigen (CEA). The phase I trial will evaluate the safety, tolerability and immunogenicity
ALGRX 3268 is a fast-acting local anesthetic and aimed at reducing pain associated with venipunctures and intravenous line placements. Treatment with ALGRX 3268 demonstrated statistically significantly less pain
Acute peripheral arterial occlusion (PAO), is the blocking of arterial blood flow to a lower limb by a blood clot. Affecting more than 100,000 people in the US
The phase I/II clinical trial, the European arm of which is already ongoing in Denmark, the UK and France, is a multi-center study of SPC2996 in patients with
Barrett’s esophagus is a precancerous condition associated with chronic heartburn that affects an estimated 1 million to 2 million Americans. Five years after joining the study, the incidence
Approximately 94% of patients treated with 0.3mg of Lucentis and 96% of those treated with 0.5mg of the drug maintained or improved vision, compared to approximately 64% of
The twelve-month, placebo-controlled study is designed to evaluate the ability of OT-551 to prevent or arrest the progression of cataracts in patients who have undergone vitrectomy surgery, a
Guidant believes that Johnson & Johnson is legally bound to complete the acquisition under their agreement signed in December 2004. However, J&J will argue that recent product recalls
Designation as a fast track drug product provides for expedited regulatory review for new drugs demonstrating the potential to address unmet medical needs for the treatment of serious
It is estimated that nearly two million Americans suffer from moderate to severe psoriasis, a chronic, immune-mediated inflammatory disease that can be both physically and emotionally debilitating. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.